Doesn't everyone think Brad Robinson owes all us shareholders an update?
It is crazy to think posters like Anthazar can represent past CEO's on this board and provide more information than the company itself provides to us shareholders.
- Where is Brad?
- Where is Sorrentino?
- Where is the board of directors?
Where is their RESPONSIBILITY to represent shareholders?
-----------------------------------------------------
1. When is Sorrentino going to be announced? This has been posted on this board for months.
For it to have gained so much traction, there must have been some truth to this specilation?
2. From the 10k notification on the Pre-IND on Osteoarthritis, has the company submitted the IND?
(this now 7 months old? What action has been taken?)
Right out of the 10K:
"The Company submitted documentation to begin the process of filing the IND on October 30, 2020, in which CoreCyte is indicated for the treatment of osteoarthritis of the knee.
On December 29, 2020, the FDA completed the Pre-IND meeting. The Company is in the process of completing its IND application and submitting to the FDA."
3. What about "Other Events" from the 10K? Is the Nebula deal done? Shouldn't we get getting an update?
On May 7, 2021, the Company entered into a strategic collaboration and development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the agreement, the Company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products, which are fulfilled by Nebula. The Company will have a revenue sharing agreement with Nebula for each product ordered by its customers.
Nebula will provide the Company with technologies and services to assist it in direct to consumer and clinical diagnostic markets in the areas of privacy technologies, such as block chain, and analytical tools. Nebula will provide access to its 30x whole genome sequencing capabilities. In addition, the Company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities will be governed by joint scientific advisory boards with representation from both companies
